Dee Rapposelli

Articles by Dee Rapposelli

Dose escalation is often applied in the management of psychosis when patients do not initially respond to therapy, but a recent study brings this strategy under question.

The rate of co-occurrence of ADHD and OCD has been reported to be as high as 60%. A question persists, however, on whether ADHD-OCD comorbidity is a true entity or whether symptoms attributed to one may be facets of a phenotype of the other.

The most common pesticide for residential use and increasingly used in agriculture may be encouraging expression of an ADHD phenotype.

Studies examining the impact of ADHD drugs on dopamine transport have been inconclusive, and preclinical research suggests that emotional factors play a greater role than stimulant therapy in fostering addictive behaviors.

©Niyaz/Shutterstock

Opioid-dependent patients presenting to an emergency department for other medical reasons are more likely to pursue addiction treatment if a specific therapy is initiated during their emergency care stay. What therapy are we talking about?

Ataxia is a relatively rare, genetic neuromuscular disorder, affecting about 150,000 persons in the United States. It is one of those disorders for which knowledge is growing but is slow to get to the practicing clinician. Hence, many persons with ataxia go for years with no diagnosis or a misdiagnosis. Alternately, because ataxia is a progressive disorder without a cure, many patients are given a stark diagnosis and sent home to cope with the disorder on their own.

In past discussions on brain-computer interfaces (BCIs), parallels were drawn between emerging applications and the idea of the "bionic man." However, a presentation by John P. Donoghue, PhD, during a "Hot Topics" plenary session on May 2 at the 59th Annual Meeting of American Academy of Neurology in Boston suggests that current neural interface technology is much more about the marvels of the human neuron and will than about machinery.

One of the most common symptoms of autonomic neuropathy is orthostatic hypotension (OH). It is treatable; however, the only FDA-approved therapeutic agent for OH, midodrine, causes supine hypertension. This hypertension occurs to a greater degree and for a longer period than bouts of OH, explained Philip A. Low, MBBS, MD, during a plenary session at the 59th Annual Meeting of the American Academy of Neurology (AAN), held in Boston, April 28 to May 5.